Becton Dickinson BioPharma Systems revenue
BioPharma Systems revenue at Becton Dickinson came to $670.0M for the quarter to 30 Jun 2026, up 6.5% from a year earlier.
As Becton Dickinson reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 6 Aug 2026.
By quarter
| Period ending | BioPharma Systems revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Jun 2026 | $670.0M | up 6.5% | 6 Aug 2026 |
| 31 Mar 2026 | $590.0M | up 2.6% | 7 May 2026 |
| 31 Dec 2025 | $429.0M | up 2.6% | 9 Feb 2026 |
| 30 Jun 2025 | $629.0M | — | 7 Aug 2025 |
| 31 Mar 2025 | $575.0M | — | 1 May 2025 |
| 31 Dec 2024 | $418.0M | — | 6 Feb 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Becton Dickinson: Medical revenue · Medical Essentials revenue · Interventional revenue · Life Sciences (earlier basis) revenue · Connected Care revenue · EMEA revenue · Greater Asia revenue · United States revenue · International revenue · financial statements
Every KPI and segment of BDX, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
